HIV Prevention

Resource Center

Clinical Insights

Podcast

Podcast

Current Barriers to HIV PrEP in the United States

02/13/2023

Video

Hepatitis C Virus Among Patients Taking PrEP

12/15/2022

Expert Q&A

Disparities in Uptake and Use of PrEP

12/09/2022

In this Q&A, Monica Gandhi, MD, MPH, discusses interventions to address the health care disparities that exist along the care continuum for certain patient populations who are at-risk for HIV...

12/09/2022

Expert Q&A

Expert Q&A

Improved Access to PrEP

12/07/2022

Podcast

Podcast

New Approaches to HIV Prevention, Management of Patients With HIV

10/27/2022

treatment

treatment

Looking Ahead: HIV Medications in the Pipeline

10/21/2022

Podcast

HIV PrEP for Older Adults

10/06/2022

Prevention

Optimization, Scale-up of PrEP

08/30/2022

Primary Care

Primary Care

PCPs and PrEP: The Role of Primary Care in Ending the HIV Epidemic

08/30/2022

dual prevention pill

The Future of Multipurpose Prevention Technologies

08/24/2022

HIV Prevention Snapshot

Reviewed by Daniel Erias, MD and Jeffrey Kwong, DNP, MPH, AGPCNP-BC

Overview

Pre-exposure prophylaxis (PrEP) is a preventive medication administered intravenously or orally to reduce the risk of human immunodeficiency virus (HIV) infection that may occur following sex or injection drug use.

Specialty Impact

Any licensed health care provider is able to prescribe PrEP. Among the health care providers who are most likely to prescribe PrEP are:

At-Risk Populations

Individuals who are at-risk of HIV transmission include:

Individuals who have had anal or vaginal sex in the past 6 months and
- had a parter with HIV
- had sex without consistently using a condom
- have been diagnosed with a sexually transmitted disease in the past 6 months
Individuals who inject drugs, have an injection partner with HIV, or who shares needles, syringes, or other drug injection equipment
Individuals who have previously been prescribed PrEP, have reported continued risk behavior, or previously used multiple courses of PrEP

Diagnostic Snapshot

The HIV Risk Incidence Index for Men Who Have Sex With Men (HIRI-MSM) and Injection Drug Users Risk Index (IDU) are often used to stratify risk in patients.

Patient Data

Sources:

Research Summaries

CONFERENCE CONVERAGE

Urine Test Shows Predictive Values for PrEP Adherence

03/14/2023

Research Summary

Post-Exposure Prophylaxis for STI Prevention for Individuals With HIV, On PrEP

01/26/2023

Research Summary

Research Summary

Increased Prevalence of STIs Among Patients Undergoing PrEP Testing

01/11/2023

preventive medicine

preventive medicine

PrEP Is Underutilized in Emergency Department Settings

11/29/2022

medication use

Global Data Assessment of HIV PrEP Awareness, Willingness to Use

03/27/2022

Researchers conducted a systematic review and meta-analysis of data among men who have sex with men to investigate the awareness of pre-exposure prophylaxis (PrEP) and willingness to use PrEP.

03/27/2022

March 2023

Current Issue

March 2023

Volume 63

Issue 3